Samantha Budd

AstraZeneca and Eli Lilly to enrol more than 1,500 patients in 15 countries to their Phase II/III study of oral beta secretase cleaving enzyme (BACE) inhibitor in development as potential treatment for Alzheimer’s disease

Phase II/III trial of AZD3293, an oral potent small molecule inhibitor of BACE, aims to enrol more than 1,500 patients…

9 years ago

The University of Bristol expects over 20,000 students to the city as the new academic year begins

The University of Bristol will be welcoming over 20,000 students to the city next week as the new academic year…

10 years ago